Generation of functional cardiomyocytes from the synoviocytes of patients with rheumatoid arthritis via induced pluripotent stem cells by Lee, J. et al.
1Scientific RepoRts | 6:32669 | DOI: 10.1038/srep32669
www.nature.com/scientificreports
Generation of Functional 
Cardiomyocytes from the 
Synoviocytes of Patients  
with Rheumatoid Arthritis  
via Induced Pluripotent  
Stem Cells
Jaecheol Lee1,2,3,*, Seung Min Jung4,*, Antje D. Ebert2,3,5,6,*, Haodi Wu1,2,3, Sebastian Diecke7, 
Youngkyun Kim1,2,3, Hyoju Yi1,2,3, Sung-Hwan Park8 & Ji Hyeon Ju8
Cardiovascular disease is a leading cause of morbidity in rheumatoid arthritis (RA) patients. This study 
aimed to generate and characterise cardiomyocytes from induced pluripotent stem cells (iPSCs) of 
RA patients. Fibroblast-like synoviocytes (FLSs) from patients with RA and osteoarthritis (OA) were 
successfully reprogrammed into RA-iPSCs and OA-iPSCs, respectively. The pluripotency of iPSCs was 
confirmed by quantitative reverse transcription-polymerase chain reaction and immunofluorescence 
staining. Established iPSCs were differentiated into cardiomyocytes using a small molecule-based 
monolayer differentiation protocol. Within 12 days of cardiac differentiation from patient-specific 
and control-iPSCs, spontaneously beating cardiomyocytes (iPSC-CMs) were observed. All iPSC-CMs 
exhibited a reliable sarcomeric structure stained with antibodies against cardiac markers and similar 
expression profiles of cardiac-specific genes. Intracellular calcium signalling was recorded to compare 
calcium-handling properties among cardiomyocytes differentiated from the three groups of iPSCs. 
RA-iPSC-CMs had a lower amplitude and a shorter duration of calcium transients than the control 
groups. Peak tangential stress and the maximum contractile rate were also decreased in RA-iPSC-
CMs, suggesting that contractility was reduced. This study demonstrates the successful generation of 
functional cardiomyocytes from pathogenic synovial cells in RA patients through iPSC reprogramming. 
Research using RA-iPSC-CMs might provide an opportunity to investigate the pathophysiology of 
cardiac involvement in RA.
Rheumatoid arthritis (RA) is a systemic autoimmune disease with unknown aetiology and is characterised by 
inflammatory polyarthritis1. Systemic inflammation often affects other organs, such as the kidney, lung and heart. 
Cardiovascular disease (CVD) is the most commonly encountered comorbidity and is the leading cause of mor-
tality and morbidity in patients with RA2–4. The prevalence of ischemic heart disease and congestive heart failure 
is significantly higher in patients with RA than in age- and sex-matched controls4–7. Recent advances in imaging 
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modalities, such as echocardiography and cardiac magnetic resonance, revealed that RA patients who are asymp-
tomatic for CVD exhibit subclinical myocardial dysfunctions8–10. Although the increased risk of myocardial dys-
function in RA is associated with atherosclerosis accelerated by chronic inflammation, factors unique to RA 
would partly contribute to the development of heart failure.
To delineate the pathophysiology of RA in the myocardium, the ideal approach would be to perform disease 
modelling using a patient’s own cells or tissues. Although animal research has provided a better understanding of 
inflammatory arthritis in RA, animal models still have a limited value for studying the systemic involvement of 
RA11. Cardiomyocytes reflecting the myocardial pathology are directly attainable from a patient’s myocardium. 
However, tissue biopsy only secures a small number of target cells and involves the patient undergoing an invasive 
procedure. Ethical issues also hinder biopsies being taken from patients without overt myocarditis. Thus, acqui-
sition of a patient’s own tissues is poorly applicable for research purposes.
Recently, disease modelling with patient-specific induced pluripotent stem cells (iPSCs) has been highlighted 
as a promising alternative to circumvent these limitations. iPSCs, pluripotent cells derived from adult somatic 
cells, were introduced by Yamanaka in 2006. Yamanaka and colleagues reprogrammed mature somatic cells into 
autologous stem cells using four canonical transcription factors, namely, OCT4, KLF4, SOX2 and c-MYC12. iPSCs 
have characteristics equivalent to embryonic stem cells (ESCs), which are able to proliferate indefinitely and dif-
ferentiate into any target cells. The pathologic features of a certain disease would be recapitulated by pathogenic 
cells differentiated from patient-derive iPSCs. Disease modelling with iPSC technologies was primarily attempted 
for inherited diseases, such as familial dilated cardiomyopathy, catecholaminergic polymorphic ventricular tach-
ycardia and spinal muscular atrophy13–15.
Although the simulation of chronic diseases with patient-specific iPSCs has not been validated, it would have 
a potential advantage in systemic diseases with a genetic predisposition. Previously, the development and pro-
gression of RA showed an association with histocompatibility leukocyte antigens, so-called shared epitopes16. 
Earlier studies also support the role of genetic background in the systemic involvement of RA17–19. Thus, we tried 
to extend RA synoviocyte-derived iPSCs beyond the joints. Here, we report the effective differentiation of cardiac 
cells from RA patient-specific iPSCs and describe their characterisation as functional cardiomyocytes.
Results
Generation and characterisation of iPSCs. Fibroblast-like synoviocytes (FLSs) of patients with RA 
(n = 3) and osteoarthritis (OA) (n = 3) and dermal fibroblasts of healthy subjects (n = 3) were efficiently repro-
grammed by lentiviral transduction of oct4, sox2, nanog and c-myc (Fig. 1a). On day 16, stem cell-like colonies 
appeared in the culture dishes of primary cells and were transferred onto a feeder-free growth layer. Subsequently, 
iPSC clones were established from patients with RA (RA-iPSCs) and patients with OA (OA-iPSCs), as well as 
a healthy control subject (control-iPSCs). All iPSCs had a normal chromosome pattern of 44 + XX or 44 + XY 
(Supplementary Figure 1).
Established iPSCs were analysed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
to determine their expression of NANOG, OCT4, ZFP-42 and SOX2. All iPSC lines exhibited similar expres-
sion levels of the pluripotency markers (Fig. 1b), irrespective of the primary cells. The pluripotency of the iPSC 
clones was further characterised by immunofluorescence staining. RA-iPSCs, OA-iPSCs and control-iPSCs were 
positively stained for well-established pluripotency markers, including OCT4, NANOG, SSEA4 and TRA-1-60 
(Fig. 1c). No significant differences were discerned among iPSC lines in terms of their expression of pluripotency 
markers.
Differentiation of iPSCs into cardiomyocytes. All iPSC clones were cultured for 20 passages to render 
the cells epigenetically closer to ESCs20,21. Established iPSCs and H7 cells were successfully differentiated into car-
diomyocytes, with beating cells observed on day 12 of cardiac differentiation (Fig. 2a and Supplementary Movie 1). 
We confirmed the purity of cardiomyocytes derived from iPSCs (iPSC-CMs) by performing flow cytometry with 
a cardiac-specific marker, cardiac troponin T type 2 (TNNT2). Using glucose deprivation to enhance purification, 
we could generate TNNT2-positive cardiomyocytes with 80–87% purity (Supplementary Figure 2). To further 
characterise the quality of iPSC-CMs, we measured the gene expression levels of TNNT2 and myosin heavy chain, 
α -isoform (MYH6), by qRT-PCR (Fig. 2b and Supplementary Figure 3). The analysis revealed no significant dif-
ference in mRNA expression among cardiomyocytes derived from RA-iPSCs, OA-iPSCs, control-iPSCs and H7 
cells (designated RA-iPSC-CMs, OA-iPSC-CMs, control-iPSC-CMs and H7-iPSC-CMs, respectively). On the 
other hand, these genes were scarcely detectable in parental iPSCs by qRT-PCR analysis.
The sarcomeric structures were similar in RA-iPSC-CMs and control-iPSC-CMs. Furthermore, immunofluo-
rescence staining of RA-iPSC-CMs and control-iPSC-CMs showed comparable expression patterns of functional 
cardiac markers such as TNNT2, myosin light chain 2a (MLC2a) and sarcomeric alpha-actinin (SA-actinin) 
(Fig. 2c).
Characterisation of patient-specific iPSC-derived cardiomyocytes. Because calcium is a crucial 
messenger in myocardial function, analysis of calcium handling allows insights into electrical excitation and 
mechanical contraction of cardiomyocytes22. Therefore, we next compared the calcium-handling parameters of 
RA-iPSC-CMs and other control cells. Representative traces showed a regular pattern of calcium transients in 
RA-iPSC-CMs and control-iPSC-CMs (Fig. 3a), with a faster beating rate of ~45 beats/min in RA-iPSC-CMs 
(Fig. 3b). The calcium-handling properties of RA-iPSC-CMs showed distinct features compared with those of 
control-iPSC-CMs and OA-iPSC-CMs. The maximum rising rate of the calcium transient and the decay Tau 
were comparable between RA-iPSC-CMs and OA-iPSC-CMs, whereas the parameters were significantly elon-
gated in control-iPSC-CMs. RA-iPSC-CMs had a significantly reduced amplitude and a shorter duration of 
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Figure 1. Generation and characterisation of RA patient-specific iPSCs. (a) RA-FLSs and healthy dermal 
fibroblasts were reprogrammed into iPSCs via lentiviral transduction of oct4, sox2, nanog and c-myc (scale 
bar, 200 μ m). (b) The mRNA levels of pluripotency genes in primary somatic cells, iPSCs and H7 cells were 
measured by quantitative reverse transcription-polymerase chain reaction. Data represent mean values of three 
independent experiments ± SEM. NS, not significant; *P < 0.05; **P < 0.01. (c) The expression of pluripotency 
markers in iPSC clones was confirmed by immunofluorescence staining with antibodies against NANOG, 
SSEA, OCT4 and TRA-1-60. The right-hand panels show merged images of iPSC colonies stained with specific 
antibodies (red and green) and DAPI (blue). RA-FLSs, fibroblast-like synoviocytes obtained from patients with 
rheumatoid arthritis (RA); RA-iPSCs, induced pluripotent stem cells (iPSCs) derived from RA patients; control-
iPSCs, iPSCs derived from a healthy control subject.
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calcium transients than the other cells (Fig. 3b). The peak tangential stress and maximum contractile rate were 
also decreased in RA-iPSC-CMs (Fig. 3c). In line with these findings, we determined the expression of calcium 
signalling-related genes in iPSC-CMs. The expression level of voltage-dependent L type calcium channel sub-
unit alpha 1C was not altered among the three groups (Fig. 3d). However, several genes critically involved in 
cardiomyocyte-specific calcium handling, such as cardiac muscle calcium-transporting ATPase (ATP2A2), 
cardiac ryanodine receptor 2 (RYR2) and phospholamban (PLN), were significantly down-regulated in 
RA-iPSC-CMs compared with the other groups (Fig. 3d).
Because FLSs are a major pathogenic component of RA, we hypothesised that the expression of inflammatory 
genes might differ between cardiomyocytes derived from RA-FLSs and cardiomyocytes derived from OA-FLSs 
and healthy dermal fibroblasts. Thus, we determined the expression of interleukin (IL)-6, IL-1, tumour necrosis 
factor (TNF)-α and TNF receptor 2 (TNFR2) to assess whether the inflammatory signature of RA-FLSs was 
retained after their differentiation into cardiomyocytes via iPSCs. Although RA-FLSs showed significantly higher 
expression levels of IL-6, IL-1, TNF-α and TNFR2 than the control groups, this difference was not observed 
following their differentiation into iPSCs and iPSC-CMs, suggesting that the inflammatory profiles are abolished 
during iPSC reprogramming and differentiation (Supplementary Figure 4).
Discussion
In the present study, we successfully reprogrammed pathogenic FLSs from RA patients into iPSCs and subse-
quently differentiated these cells into functional cardiomyocytes. To our knowledge, this is the first attempt to 
generate functional cardiomyocytes from RA patient-specific iPSCs. RA-iPSC-CMs demonstrated a characteris-
tic sarcomeric structure and expressed various cardiac-specific markers, comparable to control-iPSC-CMs and 
OA-iPSC-CMs. However, calcium-handling properties differed between RA-iPSC-CMs and the other groups.
Regardless of the parental cells, all iPSC lines showed similarities in terms of their reprogramming efficiency 
and resultant pluripotency. The reprogramming process can be affected by several factors, such as reprogramming 
Figure 2. Differentiation of patient-specific iPSCs into cardiomyocytes. (a) Beating cardiomyocytes were 
generated from control-iPSCs and RA-iPSCs after 12 days of cardiac differentiation. (b) The cellular structure 
and expression of cardiac markers in iPSC-derived cardiomyocytes were confirmed by immunofluorescence 
staining and confocal microscopy. Control-iPSC-CMs and RA-iPSC-CMs both showed characteristic 
sarcomeric structures and positive staining with antibodies against SA-actinin, TNNT2 and MLC2a (scale bar, 
200 μ m). (c) The mRNA level of a cardiac-specific gene, TNNT2, before and after cardiac differentiation in 
various cells was determined by quantitative reverse transcription-polymerase chain reaction. Data represent 
mean values determined in three independent experiments ± SEM. **P < 0.01. RA, rheumatoid arthritis; iPSCs, 
induced pluripotent stem cells; HC, healthy control; OA, osteoarthritis; SA-actinin, sarcomeric alpha-actinin; 
MLC2a, myosin light chain 2a; TNNT2, cardiac troponin T type 2.
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methods and primary somatic cells23. The characteristics of the original cells can enhance or disturb reprogram-
ming into iPSCs24,25. Synovial cells from RA patients are expected to undergo more epigenetic changes than other 
somatic cells. However, reprogramming into iPSCs was comparable between healthy dermal fibroblasts and path-
ogenic FLSs. Moreover, expression of inflammatory proteins in RA synoviocytes, such as IL-6, IL-1 and TNF-α , 
was lost after reprogramming into iPSCs.
Cardiomyocytes differentiated from control-iPSCs and patient-derived iPSCs displayed a sarcomeric structure 
with spontaneous contractile activity. We confirmed the cardiac features of iPSC-CMs by investigating expression 
of the sarcomeric components TNNT2 and MYH6. A substantial number of differentiated cells was positive for 
the cardiac marker TNNT2 in both groups, suggesting that cardiac differentiation from iPSCs was successful. The 
proportion of TNNT2-positive cardiomyocytes differentiated from iPSCs was comparable with previous reports.
Although the reprogramming and differentiation processes showed no significant differences between 
the groups, RA-iPSC-CMs had different calcium-handling properties compared with OA-iPSC-CMs and 
Figure 3. Characterisation of cardiomyocytes derived from patient-specific iPSCs. (a) Representative line-
scan images and spontaneous calcium signalling of RA-iPSC-CMs and control-iPSC-CMs showed regular 
calcium transients. (b) The calcium-handling properties of RA-iPSC-CMs, OA-iPSC-CMs and control-
iPSC-CMs were compared by examining calcium-handling parameters. (c) Contractility measurements 
were recorded on single, spontaneously beating cardiomyocytes derived from RA-iPSCs and control-iPSCs. 
(d) Expression of calcium signalling-related genes was measured in iPSC-CMs using quantitative reverse 
transcription-polymerase chain reaction. Data represent mean values determined in three independent 
experiments ± SEM. NS, not significant; *P < 0.05; **P < 0.01. RA, rheumatoid arthritis; RA-iPSCs, induced 
pluripotent stem cells (iPSCs) derived from RA patients; HC, healthy control; control-iPSCs, iPSCs derived 
from a healthy control subject; CACNA1C, voltage-dependent L type calcium channel subunit alpha 
1C; ATP2A2, cardiac muscle calcium-transporting ATPase; RYR2, cardiac ryanodine receptor 2; PLN, 
phospholamban.
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control-iPSC-CMs. The most prominent finding was the low amplitude and short duration of calcium tran-
sients in RA-iPSC-CMs, suggesting that calcium currents were decreased. The contractile activity represented 
by peak tangential stress and the maximum contractile rate was also decreased in RA-iPSC-CMs. Reduced 
expression of ATP2A2 and RYR2, which encode the calcium channels in cardiac myocytes, may account for the 
calcium-handling defect in RA-iPSC-CMs. However, the effect of down-regulated PLN can be confusing. PLN is a 
membrane protein that inhibits sarcoplasmic/endoplasmic reticulum calcium-ATPase, which pumps cytoplasmic 
calcium into the sarcoplasmic reticulum. Inactivation of PLN in RA-iPSC-CMs enhances the storage of calcium 
in the sarcoplasmic reticulum, leading to promotion of relaxation and the following contraction. Thus, the com-
bined effect of reduced expression of calcium handling-related genes in RA-iPSC-CMs requires further research.
Experimental studies of cardiomyopathies have been restricted due to the limitations of cellular resources; 
therefore, the electrophysiological properties of the myocardium in RA patients have not been elucidated. We 
only infer cardiogenic dysfunction based on the electrocardiographic abnormalities. A population-based study 
revealed prolongation of the corrected QT interval in RA patients26. Based on the association between the 
C-reactive protein level and QT interval27,28, the inflammatory burden is considered to prolong the QT interval. 
However, the underlying mechanism and the myocardial pathology that is susceptible to inflammation remain to 
be determined. iPSC technologies would allow evaluation of myocardial dysfunction in RA, as well as the patho-
logic response of the myocardium in the inflammatory milieu in RA.
In this study, we employed OA-iPSCs as another comparator. Patients with OA have been frequently regarded 
as controls for RA patients29. RA and OA often share similarities in terms of joint involvement; however, the prin-
cipal pathophysiology of arthritis differs30. RA is an inflammatory disease characterised by pannus formation, 
while OA is a degenerative disease affected by mechanical injury and pressure overload. This disparity makes it 
possible to investigate the effect of the inflammatory burden on the pathophysiology of RA.
The limitation of this study is that a relatively small sample size was used to reveal the pathophysiologic fea-
tures of RA-related cardiomyopathies. Three patients might be insufficient to show the disease characteristics, 
rather than individual characteristics. However, calcium-handling properties consistently differed between 
RA-iPSC-CMs and the other groups, suggesting that they reflect the disease. The recruitment of more patients 
would improve the power to simulate heart disease in RA. In addition, the effect of chronic inflammation was 
not fully considered in this model. Although disease modelling using iPSC technologies has mainly focused on 
primary myocardial disease31, simulation of cardiomyopathies secondary to metabolic disease can be attempted. 
Cardiomyocytes differentiated from patient-derived iPSCs can be manipulated by environmental stress to reca-
pitulate the disease phenotype32. The response of RA-iPSC-CMs to inflammatory molecules might provide a 
better understanding of the cardiac involvement of RA.
Nevertheless, to our knowledge, this is the first study to report the successful differentiation of iPSCs derived 
from RA patients into cardiomyocytes. We confirmed the general features of the differentiated cardiomyocytes by 
several reliable methods including the following: (1) visualisation of beating cells, (2) analysis of the expression 
of cardiac-specific markers via qRT-PCR and immunostaining, and (3) calcium imaging to show relevant cal-
cium transient waveforms. These iPSC-CMs would provide more opportunities for disease modelling and drug 
screening. 
In conclusion, we generated functional cardiomyocytes using iPSCs derived from synoviocytes of patients 
with RA and OA. iPSC-CMs demonstrate a possible application of patient-derived iPSCs in rheumatology. This 
concept can be theoretically extended to other cell types, including osteocytes, chondrocytes, immune cells and 
neurons. We anticipate that ongoing progress in iPSC research and technologies will provide valuable informa-
tion in real clinical settings of rheumatology.
Materials and Methods
Derivation of human iPSCs. FLSs were isolated from the synovial tissues of three patients with RA and 
three patients with OA and used to generate patient-specific iPSCs. The synovial tissues were obtained dur-
ing a surgical procedure for therapeutic purposes and stored anonymously in the tissue bank of the Catholic 
Rheumatism Research Center prior to reprogramming. Tissues were minced and resuspended in Dulbecco’s 
modified Eagle’s medium (DMEM; Gibco, Invitrogen Corporation) containing 0.01% collagenase, and then incu-
bated for 4 h at 37 °C with vigorous shaking. Cells were washed and resuspended in DMEM supplemented with 
20% foetal bovine serum (Gibco) and 1% penicillin/streptomycin solution (Gibco). Cells were cultured until the 
adherent fibroblasts became confluent. Dermal fibroblasts were acquired from a healthy volunteer with informed 
consent and reprogrammed into control-iPSCs for comparative analyses.
Reprogramming of somatic cells into iPSCs was performed as previously described33. Briefly, the primary cells 
were incubated with a lentiviral construct encoding oct4, sox2, nanog and c-myc in the presence of polybrene. 
The medium was replaced after 24 h, and then every other day for the next 6 days. On day 7, cells were trans-
ferred onto Matrigel-coated 6-well plates containing DMEM/GlutaMAX™ (Life Technologies) supplemented 
with 10% foetal bovine serum and a Rho kinase inhibitor, Y-27632 (10 mM prepared in 100 μ l of Dulbecco’s 
phosphate-buffered saline) (Selleck Chemicals). After the cells adhered, the medium was changed to chemically 
defined Essential 8™ medium (Life Technologies). On day 16, colonies were manually picked and transferred to a 
fresh Matrigel-coated culture dish. The medium was changed daily, and cells were passaged every 3–4 days using 
Accutase Cell Detachment Solution (Global Cell Solutions).
Ethics. All procedures and methods involving human samples were in accordance with approved guidelines. 
We received informed consents from all of the participants. This study was approved by the Institutional Review 
Board of the Catholic University of Korea (KC13TISI0577).
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Differentiation of iPSCs into cardiomyocytes. We utilised a chemically defined monolayer differ-
entiation protocol for cardiac differentiation34,35. Briefly, iPSCs at ~90% confluency were incubated with dif-
ferentiation basal medium, namely, RPMI 1640 medium (Invitrogen) containing 2% B27 supplement minus 
insulin (Invitrogen). CHIR99021, a selective glycogen synthase kinase 3β inhibitor (6-[[2-[[4-(2,4-dichloroph
enyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile; 10 mM in 
15 μ l of dimethyl sulfoxide), was also added to the differentiation basal medium. On day 2, the medium was 
replaced with differentiation basal medium lacking CHIR99021, and, on day 3, the Wnt antagonist IWR-1 
(4-(1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl)-N-8-quinolinyl-benzamide; 10 mM in 
6 μ l of dimethyl sulfoxide) was added to the medium. After another 48 h, the medium was replaced with differ-
entiation basal medium without any inhibitors. On day 7, the cells were incubated with complete cardiomyocyte 
medium, namely, RPMI 1640 medium containing 2% B27 supplement plus insulin (Invitrogen). The medium was 
changed every other day. Monolayers of iPSC-CMs were cultured for ~30 days and subsequently dissociated for 
experimental use with TrypLE™ Express (Life Technologies).
Immunofluorescence staining and confocal microscopy. Established iPSCs were fixed with 4% para-
formaldehyde prepared in phosphate-buffered saline. Following permeabilisation with 0.3% Triton X-100, iPSCs 
were stained with primary antibodies against OCT3/4, SSEA4, NANOG (all from Santa Cruz Biotechnology, Inc.) 
and TRA-1-60 (Chemicon). iPSC-CMs were then passaged onto Matrigel-coated 12 mm glass coverslips, followed 
by staining with antibodies against TNNT2 (Thermo Scientific and Abcam), MLC2a (Santa Cruz Biotechnology) 
and SA-actinin (Sigma Chemical Co). After reaction with the primary antibodies, cells were incubated with the 
appropriate Alexa Fluor-conjugated secondary antibodies (Santa Cruz Biotechnology or Life Technologies).
Images of the stained cells were obtained under a bright field microscope (Leica). Confocal images were taken 
using a 63× Plan-Apochromat oil immersion objective (Carl Zeiss) and a LSM 510 Meta confocal microscope 
(Carl Zeiss). Images were analysed using ZEN software (Carl Zeiss) and ImageJ software (National Institutes of 
Health).
RNA extraction and qRT-PCR. Total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen). The 
reverse transcription reaction was performed using the iScript™ cDNA Synthesis Kit (Bio-Rad), and qRT-PCR 
was performed using iQ® SYBR™ Green Supermix (Bio-Rad) and a CFX96™ real-time PCR detector (Bio-Rad). 
Relative mRNA levels were normalised against those of 18S mRNA for each reaction. The primers for qRT-PCR 
are presented in the Supplementary Table.
Intracellular calcium imaging. iPSC-CMs were plated onto Matrigel-coated 8-well Lab-Tek® II coverglass 
imaging chambers (Thermo Fisher Scientific, Inc.) at a density of 20,000 cells per well. After 3–4 days, cells were 
loaded with 5 μ M Fluo-4 AM prepared in Tyrode’s solution (140 mM NaCl, 5.4 mM KCl, 1 mM MgCl2, 10 mM 
glucose, 1.8 mM CaCl2 and 10 mM HEPES, pH adjusted to 7.4 with NaOH at room temperature) for 5 min at 
37 °C. Next, cells were washed three times with pre-warmed Tyrode’s solution. Spontaneous calcium signalling 
in iPSC-CMs was analysed using a LSM 510 Meta confocal microscope equipped with a 63× Plan-Apochromat 
oil immersion objective. Signalling was recorded in line-scanning mode (512 pixels × 1920 lines) at a speed of 
3.2 μ s/pixel. A custom-made script based on the Interactive Digital Language was used for image processing. The 
extracellular background was subtracted from the calcium signalling, and the calcium signal was normalised to 
the intracellular basal line. The transient amplitude was expressed as ∆ F/F0.
Statistical analysis. All quantifiable experimental data are presented as mean ± standard error of mean 
(SEM). Statistical significance was determined by the Mann-Whitney U test or an analysis of variance followed by 
Bonferroni’s post hoc test. P-values < 0.05 were considered statistically significant. Data analysis was performed 
using SAS 9.1 software (SAS Institute).
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